Literature DB >> 702352

Reversal of inotropic effects of digoxin by specific antibodies and their Fab fragments in the conscious dog.

H R Ochs, S F Vatner, T W Smith.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 702352

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


× No keyword cloud information.
  8 in total

1.  Functional capacity of immunoglobulin G preparations and the F(ab')2 split product.

Authors:  R W Steele; R W Steele
Journal:  J Clin Microbiol       Date:  1989-04       Impact factor: 5.948

2.  Proceedings of the Fiftieth Anniversary Meeting of the British Pharmacological Society, University of Oxford, 16-18 September 1981. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1981-12       Impact factor: 8.739

3.  The biological properties of immunoglobulin G and its split products [F(ab')2 and Fab].

Authors:  H H Sedlacek; P Gronski; T Hofstaetter; E J Kanzy; H U Schorlemmer; F R Seiler
Journal:  Klin Wochenschr       Date:  1983-08-01

4.  Suicidal digoxin poisoning: conventional treatment and antibody therapy.

Authors:  T Hess; H U Dubach; G Scholtysik; W Riesen
Journal:  Klin Wochenschr       Date:  1982-04-15

Review 5.  Fab antibody fragments: some applications in clinical toxicology.

Authors:  Robert J Flanagan; Alison L Jones
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

6.  The influence of digoxin antibodies on digoxin disposition and effect: studies in guinea-pigs and HeLa cells.

Authors:  N M Griffiths; D S Hewick; J F Lamb; I H Stevenson
Journal:  Br J Pharmacol       Date:  1985-01       Impact factor: 8.739

7.  Differing sensitivities of Purkinje fibers and myocardium to inhibition of monovalent cation transport by digitalis.

Authors:  J C Somberg; W H Barry; T W Smith
Journal:  J Clin Invest       Date:  1981-01       Impact factor: 14.808

Review 8.  Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity.

Authors:  M R Ujhelyi; S Robert
Journal:  Clin Pharmacokinet       Date:  1995-06       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.